ArticleBMJ open respiratory research2026

Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.

Henrik Watz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.